Physician profile
Morgan E Schubbe
NPI 1821447418
$2,144.25
in general payments reported to CMS, 2019-2025
22 companies · $480 in 2025
The $480 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $22.90 · 2021: $151 · 2022: $398 · 2023: $359 · 2024: $502 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,082.36 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, Axonics, Ams 700 |
| Sumitomo Pharma America, INC. | $147.57 | 2023-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $136.43 | 2024 | |
| Intuitive Surgical, INC. | $134.44 | 2024 | |
| Immunitybio, INC. | $104.16 | 2025 | |
| Axonics, INC. | $92.80 | 2022-2023 | Axonics |
| Astellas Pharma US INC | $51.03 | 2023-2025 | Xtandi |
| Janssen Biotech, INC. | $50.97 | 2023-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $37.06 | 2023-2024 | |
| Valencia Technologies Corporation | $36.24 | 2023 | Ecoin Device Kit |
| Dendreon Pharmaceuticals LLC | $35.82 | 2023-2025 | Provenge |
| Olympus America INC. | $33.34 | 2025 | Itind System |
| Abbvie INC. | $31.01 | 2023-2025 | Botox |
| Pfizer INC. | $23.31 | 2023 | |
| Blue Earth Diagnostics | $21.24 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.20 | 2023 | Keytruda |
| Alnylam Pharmaceuticals INC. | $20.46 | 2023 | Givlaari |
| Novartis Pharmaceuticals Corporation | $18.26 | 2023 | |
| Sun Pharmaceutical Industries INC. | $18.15 | 2024 | |
| Smith+Nephew, INC. | $16.81 | 2022 | |
| Tolmar, INC. | $16.62 | 2025 | Eligard, Jatenzo |
| Teleflex LLC | $14.97 | 2024 | Urolift |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Schubbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.